🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05973097
Recruiting Not applicable

Treatment of Oral Lichen Planus With Paeoniflorin and Photodynamic Therapy

NCT05973097 · tracked via the Priya Life Science China tracker
Sponsor
Peking University Third Hospital
Phase
Not applicable
Started
2023-07-30
Last updated
2023-08-02

Condition(s) studied

Oral Lichen Planus

Investigational drug(s) / intervention(s)

total glucosides of paeony treatmentphotodynamic therapy treatmentglucosides of paeony and photodynamic therapy combined treatment

total glucosides of paeony treatment: Total glucosides of paeony capsules were given 0.6 g once, 3 times a day.

photodynamic therapy treatment: Cover the lesion with photosensitizer and fix it. Remove the photosensitizer and treat with laser diode.

glucosides of paeony and photodynamic therapy combined treatment: Glucosides of paeony and photodynamic therapy are combined for the treatment

Study summary

Oral lichen planus (OLP) is a common chronic inflammatory disease of the oral mucosa and is considered a precancerous condition. It is characterized by white reticular changes in the oral mucosa, which can progress to erosions and cause pain in severe cases. The pathogenesis of OLP is still unclear, but it is believed to be a T-lymphocyte-mediated autoimmune disease. Currently, only symptomatic treatments are available, and there is no definitive cure.

In this project, we plan to use TCM differentiation to categorize OLP patients and conduct a randomized controlled clinical trial to demonstrate the enhanced therapeutic effect of paeoniflorin combined with photodynamic therapy for OLP. The implementation of this project will provide new insights into the clinical management of OLP, improve our understanding of the treatment mechanisms, and have important theoretical and clinical implications.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * patients with oral lichen planus * male or female patients older than 18 years of age * patients willing to participate with signed informed consent. Exclusion Criteria: * pregnant or lactating * had serious systemic diseases of the heart, lung, liver, and kidney, or had tumors * were unwilling to participate in the experiment.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Peking University Third Hospital Beijing China Recruiting

More Peking University Third Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05973097 on ClinicalTrials.gov ↗ ← All trials in China